154 related articles for article (PubMed ID: 37828817)
21. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
[TBL] [Abstract][Full Text] [Related]
22. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
Nakamura S; Murakami N; Inaba K; Wakita A; Kobayashi K; Takahashi K; Okamoto H; Umezawa R; Morota M; Sumi M; Igaki H; Ito Y; Itami J
BMC Cancer; 2016 May; 16():296. PubMed ID: 27142069
[TBL] [Abstract][Full Text] [Related]
23. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
[TBL] [Abstract][Full Text] [Related]
24. Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
Aluwini S; Busser WM; Alemayehu WG; Boormans JL; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
Radiother Oncol; 2015 Nov; 117(2):252-7. PubMed ID: 26409832
[TBL] [Abstract][Full Text] [Related]
25. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life.
Jo Y; Junichi H; Tomohiro F; Yoshinari I; Masato F
BJU Int; 2005 Jul; 96(1):43-7. PubMed ID: 15963118
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Biochemical Control of a Prospective Cohort of Prostate Cancer Patients Treated With Interstitial Brachytherapy Versus Radical Prostatectomy.
Sanmamed N; Locke G; Crook J; Liu A; Raman S; Glicksman R; Chung P; Berlin A; Fleshner N; Helou J
Clin Oncol (R Coll Radiol); 2023 Apr; 35(4):262-268. PubMed ID: 36737311
[TBL] [Abstract][Full Text] [Related]
27. Cs-131 prostate brachytherapy boost and effect of hydrogel rectal spacer on long-term patient-reported rectal bleeding and bowel quality of life.
Abdelhakiem MK; Keller A; Bajpai RR; Smith RP; Beriwal S; Benoit R
Brachytherapy; 2023; 22(6):808-821. PubMed ID: 37648596
[TBL] [Abstract][Full Text] [Related]
28. Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy.
Imai Y; Urabe F; Iwatani K; Nakazono M; Tashiro K; Honda M; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
Int J Clin Oncol; 2023 May; 28(5):698-706. PubMed ID: 36814038
[TBL] [Abstract][Full Text] [Related]
29. Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer.
Contreras JA; Wilder RB; Mellon EA; Strom TJ; Fernandez DC; Biagioli MC
Int Braz J Urol; 2015; 41(1):40-5. PubMed ID: 25928509
[TBL] [Abstract][Full Text] [Related]
30. A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men.
Li Y; Chan Kong Ngai T; Zhou S; Yap Haw Hwong J; Pang Pei Ping E; Ong Li Kuan A; Wang Lian Chek M; Chua Lee Kiang M; Looi WS; Nei WL; Chua ET; On WLK; Tan Wee Kiat T; Yuen Shyi Peng J; Tuan Kit Loong J
Acta Oncol; 2021 Oct; 60(10):1291-1295. PubMed ID: 34259123
[TBL] [Abstract][Full Text] [Related]
31. Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?
Zaorsky NG; Doyle LA; Hurwitz MD; Dicker AP; Den RB
Expert Rev Anticancer Ther; 2014 Jan; 14(1):39-50. PubMed ID: 24124755
[TBL] [Abstract][Full Text] [Related]
32. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
33. Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer.
Burchardt W; Skowronek J
J Contemp Brachytherapy; 2018 Feb; 10(1):1-9. PubMed ID: 29619050
[TBL] [Abstract][Full Text] [Related]
34. Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer.
Makino T; Nakashima K; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Kumano T; Mizokami A
Anticancer Res; 2019 Jan; 39(1):477-486. PubMed ID: 30591498
[TBL] [Abstract][Full Text] [Related]
35. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
36. [Brachytherapy in men with prostate cancer: update on indications and outcomes].
Pinto F; Calarco A; Recupero SM; Totaro A; Sacco E; Bassi P
Urologia; 2013; 80(2):87-98. PubMed ID: 23852925
[TBL] [Abstract][Full Text] [Related]
37. The evolution of brachytherapy for prostate cancer.
Zaorsky NG; Davis BJ; Nguyen PL; Showalter TN; Hoskin PJ; Yoshioka Y; Morton GC; Horwitz EM
Nat Rev Urol; 2017 Jun; 14(7):415-439. PubMed ID: 28664931
[TBL] [Abstract][Full Text] [Related]
38. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials.
Peinemann F; Grouven U; Bartel C; Sauerland S; Borchers H; Pinkawa M; Heidenreich A; Lange S
Eur Urol; 2011 Nov; 60(5):881-93. PubMed ID: 21763066
[TBL] [Abstract][Full Text] [Related]
39. Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer.
Barnes J; Kennedy WR; Fischer-Valuck BW; Baumann BC; Michalski JM; Gay HA
J Contemp Brachytherapy; 2019 Aug; 11(4):320-328. PubMed ID: 31523232
[TBL] [Abstract][Full Text] [Related]
40. Acute toxicity and health-related quality of life outcomes of localized prostate cancer patients treated with magnetic resonance imaging-guided high-dose-rate brachytherapy: A prospective phase II trial.
Sanmamed N; Adleman J; Berlin A; Borg J; Lao B; Weersink R; Simeonov A; Rink A; Beiki-Ardakani A; Menard C; Chung P; Helou J
Brachytherapy; 2023; 22(1):58-65. PubMed ID: 36414526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
